Generate Biomedicines officer reports stock trades

Generate Biomedicines, Inc. Chief People Officer Beth Grous reported two insider transactions.

Accepted by SEC EDGAR 03/02/2026 - 06:05 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Generate Biomedicines, Inc. Chief People Officer Beth Grous reported two insider transactions. An account held by her spouse bought 300 shares of common stock at $16.00 per share, recorded as indirect ownership. She also received a grant of 114,020 stock options, which vest in forty-eight equal monthly installments starting after February 19, 2026, contingent on continued service.

Insider Trade Summary

Net Buyer: 300 shares

Net Buy 2 txns

Insider Grous Beth

Role Chief People Officer

Bought 300 shs ($5K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	300	$16.00	$5K
Grant/Award	Stock Option (Right to Buy)	114,020	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 114,020 contracts (Direct); Common Stock — 300 shares (Indirect, By Spouse)

Holdings Before and After: Stock Option (Right to Buy), 0 to 114,020 contracts (Direct); Common Stock, 0 to 300 shares (Indirect, By Spouse)

Other Insiders: 3 other insiders reported open-market purchases of this stock in the 30 days up to this filing.

Footnotes (1)

1. F1. The shares underlying this option shall vest in forty-eight equal monthly installments following February 19, 2026, subject to the Reporting Person's continued service on each such vesting date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did GENB officer Beth Grous report?

Beth Grous reported two insider transactions: an indirect open-market purchase of 300 Generate Biomedicines (GENB) common shares and a grant of 114,020 stock options. The purchase was at $16.00 per share, while the options vest over four years, subject to continued service.

How many Generate Biomedicines (GENB) shares did Beth Grous buy?

An entity associated with Beth Grous bought 300 GENB common shares. The transaction was an open-market purchase at $16.00 per share, reported as indirect ownership held by her spouse, and brought total indirectly held common shares reported in this filing to 300.

What are the terms of Beth Grous’ 114,020 GENB stock options?

Beth Grous received 114,020 Generate Biomedicines stock options as a grant. According to the disclosure, these options vest in forty-eight equal monthly installments following February 19, 2026, and each vesting date requires her continued service with the company for the tranche to vest.

Is Beth Grous’ GENB share ownership direct or indirect?

The 300 GENB common shares reported as purchased are held indirectly, listed as “By Spouse.” This means the shares are owned through her spouse’s account, while the 114,020 stock options are reported as directly owned derivative securities in her name.

What role does Beth Grous hold at Generate Biomedicines (GENB)?

Beth Grous serves as Chief People Officer at Generate Biomedicines. Her Form 4 filing reflects equity-related compensation and an indirect share purchase, providing transparency about how a senior executive’s economic exposure to GENB stock changed with these transactions.

Over what period will Beth Grous’ GENB options vest?

The 114,020 GENB stock options vest over forty-eight months. Vesting occurs in equal monthly installments following February 19, 2026, and each monthly tranche requires Beth Grous to remain in service with the company on that specific vesting date to receive it.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Grous Beth

(Last) (First) (Middle)

GENERATE BIOMEDICINES, INC.

101 SOUTH STREET, SUITE 900

(Street)

SOMERVILLE MA 02143

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Generate Biomedicines, Inc. [ GENB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief People Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/26/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/02/2026		P		300	A	$16	300	I	By Spouse

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$16	02/26/2026		A		114,020		(1)	02/25/2036	Common Stock	114,020	$0	114,020	D

Explanation of Responses:

1. The shares underlying this option shall vest in forty-eight equal monthly installments following February 19, 2026, subject to the Reporting Person's continued service on each such vesting date.

	/s/ Michael Wolf, Attorney-in-Fact	03/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.